Scilex Holding (SCLXW) Enterprise Value (2020 - 2026)
Scilex Holding (SCLXW) recorded quarterly Enterprise Value of -$149.9 million in Q1 2026, down 891.17% quarter-over-quarter from -$15.1 million in Q4 2025, and down 2484.9% on a YoY basis from $6.3 million in Q1 2025.
Scilex Holding (SCLXW) Enterprise Value (2020 - 2026) Analysis & Trends
Scilex Holding's Enterprise Value history runs 7 years deep, the most recent figure standing at -$149.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 2484.9% year-over-year to -$149.9 million; the TTM figure through Mar 2026 stood at -$149.9 million (down 2484.9% YoY), while the FY2025 annual figure was -$15.1 million, down 362.29% from the prior year.
- Enterprise Value was -$149.9 million for Q1 2026 at Scilex Holding, down from -$15.1 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$69922.0 in Q3 2022 to a low of -$149.9 million in Q1 2026.
- Historically, Enterprise Value has averaged -$30.6 million across 5 years, with a median of -$4.1 million in 2025.
- Biggest YoY gain for Enterprise Value was 98.48% in 2022; the steepest drop was 55034.43% in 2022.
- A 5-year view of Enterprise Value shows it stood at -$2.2 million in 2022, then tumbled by 79.53% to -$3.9 million in 2023, then gained by 16.55% to -$3.3 million in 2024, then plunged by 362.29% to -$15.1 million in 2025, then sank by 891.17% to -$149.9 million in 2026.
- The last three Enterprise Value figures came in at -$149.9 million (Q1 2026), -$15.1 million (Q4 2025), and -$3.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -4.96 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | -5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -22.05 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -9.35 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -10.45 Bn |
| 10 | Scilex Holding | - | - | 4.15 Mn | -149.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -149.92 Mn |
| Dec 31, 2025 | -15.13 Mn |
| Sep 30, 2025 | -3.68 Mn |
| Jun 30, 2025 | -4.10 Mn |
| Mar 31, 2025 | -5.80 Mn |
| Dec 31, 2024 | -3.27 Mn |
| Sep 30, 2024 | -77,000.00 |
| Jun 30, 2024 | -6.89 Mn |
| Mar 31, 2024 | -1.82 Mn |
| Dec 31, 2023 | -3.92 Mn |
| Sep 30, 2023 | -2.00 Mn |
| Jun 30, 2023 | -34.12 Mn |
| Mar 31, 2023 | -5.10 Mn |
| Dec 31, 2022 | -2.18 Mn |
| Sep 30, 2022 | -69,922.00 |
| Jun 30, 2022 | -142.04 Mn |
| Mar 31, 2022 | -140.58 Mn |
| Dec 31, 2021 | -143.75 Mn |
| Sep 30, 2021 | -115,642.00 |
| Jun 30, 2021 | -257,621.00 |